September 8, 2020, Vol 324, No. 10, Pages 919-1016
An Inactivated Virus Candidate Vaccine to Prevent COVID-19
Mark J. Mulligan, MD
… In summary, this preliminary report by Xia et al10 provides important interim safety, tolerability, and immune response results for a β-propiolactone–inactivated whole-virus vaccine against COVID-19. These interim data are of interest given the urgent global need for protective COVID-19 vaccines. With 7.8 billion individuals worldwide at risk for SARS-CoV-2 infection and COVID-19 morbidity and mortality, humanity needs as many safe and protective COVID-19 vaccines as possible.